Plain-English translation of NCT04160507 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers at Duke University are studying why African Americans develop kidney failure at much higher rates than other groups. They believe a genetic change called APOL1 plays a role, but they don't yet understand exactly how it damages the kidneys. This study will collect blood samples that can be transformed into kidney-like cells in the lab, allowing scientists to watch how the genetic change affects these cells and causes kidney disease.
Only some people with the APOL1 genetic change develop kidney failure, and scientists don't yet understand why. By studying cells grown from participants' blood, researchers hope to discover the cellular mechanisms that link this genetic change to kidney disease—knowledge that could eventually lead to new treatments.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will donate a blood sample at Duke University or a nearby location. The researchers will use your blood to create kidney-like cells in the laboratory that they can study over time. You may be asked to share information about your medical history and kidney health. The study is ongoing and aims to enroll about 200 participants total.
AI-generated summary from trial data · Aug 30, 2026 · Not medical advice
United States
Enrollment target
~200 participants
Started
December 2019
Primary completion
November 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in August 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Opeyemi Olabisi, MD/PHD
Duke University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.